VTE treatment & prophylaxis ⭐
vte-treatment · high-yield
← back to Hematology & Oncology
Summary
Second update to the CHEST 9th edition guidelines on antithrombotic therapy for VTE, providing 29 guidance statements (13 strong recommendations) across 17 PICO questions. Major changes from prior versions include a strong recommendation for DOACs over VKA as first-line treatment-phase therapy, a strong recommendation for oral Xa inhibitors over LMWH in cancer-associated thrombosis, new guidance on antiphospholipid syndrome favoring VKA over DOACs, and endorsement of reduced-dose DOACs for extended-phase therapy. Anticoagulation phases are formally defined as initiation (5-21 days), treatment (3 months), and extended (no preplanned stop date).
Current guideline: CHEST 2021 Antithrombotic Therapy for VTE · 
download Anki sub-deck